Remicade: first biological agent for paediatric ulcerative colitis

Remicade (infliximab) is now licensed for the treatment of severe active ulcerative colitis in children aged 6-17 years.

Remicade, is the first licensed anti-TNF preparation for ulcerative colitis treatment in children | SCIENCE PHOTO LIBRARY
Remicade, is the first licensed anti-TNF preparation for ulcerative colitis treatment in children | SCIENCE PHOTO LIBRARY

It may be used in those who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or if such therapies are contraindicated or not tolerated.

Licensed dose

The recommended dose of infliximab is 5mg/kg given as an intravenous infusion over 2 hours, repeated 2 weeks and 6 weeks after the first infusion, and every 8 weeks thereafter. Study data do not support continued use in children who fail to respond within the first 8 weeks of treatment.

Clinical study

A total of 60 children aged 6–17 years with moderate to severe active ulcerative colitis (Mayo score of 6–12; endoscopic subscore ≥2) who had an inadequate response to conventional therapy were recruited for a 54-week, multicentre, open-label study of infliximab. Altogether, 73.3% of patients showed a clinical response to infliximab at week 8, with an overall remission rate of 28.6% at study end.

Also indicated in adults

Remicade is also indicated for the treatment of moderate to severe active ulcerative colitis in adults.

View Remicade drug record

Further information: Schering-Plough Ltd


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases